Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020–2022)
Ретроспективное исследование и исходы лечения 307 кошек с инфекционным перитонитом кошек препаратами ремдесивира и GS-441524, изготовленными в ветеринарных аптеках на законных основаниях (2020–2022 гг.)
2023-09-01
SCID: 54.1/7vtsyvks
Discuss with AI
GS-441524feline infectious peritonitisremdesivirtreatment outcomesveterinary compounded products
Figures from the paper
Abstract (AI)
OBJECTIVES: Feline infectious peritonitis (FIP) is a serious disease that arises due to feline coronavirus infection. The nucleoside analogues remdesivir and GS-441524 can be effective in its treatment, but most studies have used unregulated products of unknown composition. The aim of the present study was to describe the treatment of FIP using legally sourced veterinary-prescribed regulated veterinary compounded products containing known amounts of remdesivir (injectable) or GS-441524 (oral tablets). METHODS: Cats were recruited via email advice services, product sales contacts and study publicity. Cats were excluded if they were deemed unlikely to have FIP, were not treated exclusively with the veterinary compounded products, or if there was a lack of cat and/or treatment (including response) data. Extensive cat and treatment data were collected. RESULTS: Among the 307 cats recruited, the predominant type of FIP was most commonly abdominal effusive (49.5%) and then neurological (14.3%). Three treatment protocols were used; remdesivir alone (33.9%), remdesivir followed by GS-441524 (55.7%) and GS-441524 alone (10.4%). The median (range) initial treatment period duration and longest follow-up time point after starting treatment were 84 (1-330) days and 248 (1-814) days, respectively. The most common side effect was injection pain (in 47.8% of those given subcutaneous remdesivir). Of the 307 cats, 33 (10.8%) relapsed, 15 (45.5%) during and 18 (54.5%) after the initial treatment period. At the longest follow-up time point after completion of the initial treatment period, 84.4% of cats were alive. The cats achieving a complete response within 30 days of starting treatment were significantly more likely to be alive at the end of the initial treatment period than those cats that did not. CONCLUSIONS AND RELEVANCE: Legally sourced remdesivir and GS-441524 products, either alone or used sequentially, were very effective in the treatment of FIP in this group of cats. Variable protocols precluded statistical comparison of treatment regimens.
Key Findings
1
Abdominal effusive FIP was predominant (49.5%), followed by neurological FIP (14.3%); treatment most commonly involved remdesivir followed by oral GS-441524 (55.7%).
2
At the longest follow-up after initial treatment, 84.4% of cats were alive; achieving complete response within 30 days was significantly associated with survival through the initial treatment period.
3
Relapse occurred in 33 cats (10.8%), including 15 during and 18 after the initial treatment period.
4
The median initial treatment duration was 84 days, with follow-up extending to a median of 248 days; injection pain occurred in 47.8% of cats receiving subcutaneous remdesivir.
5
The study concluded that legally sourced remdesivir and GS-441524, used alone or sequentially, were very effective for treating FIP in this cohort.
6
This retrospective study evaluated 307 cats with FIP treated exclusively with legally sourced, veterinary-prescribed compounded remdesivir and/or GS-441524 products.
Research Object
307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded remdesivir and GS-441524 preparations
Research Subject
Treatment outcomes, response, relapse, survival, and adverse effects associated with remdesivir and GS-441524 therapy
Publication Details
Publication Date
2023-09-01
Journal
Publisher
ISSN
Cited by
103
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai13
An update on feline infectious peritonitis: Virology and immunopathogenesis2014
Diagnosis of Feline Infectious Peritonitis: A Review of the Current Literature2019
Diagnosis of feline infectious peritonitis: Update on evidence supporting available tests2018
Emergence of Pathogenic Coronaviruses in Cats by Homologous Recombination between Feline and Canine Coronaviruses2014
Clinicopathological findings associated with feline infectious peritonitis in Sydney, Australia: 42 cases (1990–2002)2005
Epidemiology of feline infectious peritonitis among cats examined at veterinary medical teaching hospitals2001
Risk factors for feline infectious peritonitis in Australian cats2012
A retrospective study of clinical and laboratory features and treatment on cats highly suspected of feline infectious peritonitis in Wuhan, China2021
Limitations of using feline coronavirus spike protein gene mutations to diagnose feline infectious peritonitis2017
An outbreak of feline infectious peritonitis in a Taiwanese shelter: epidemiologic and molecular evidence for horizontal transmission of a novel type II feline coronavirus2013
Phylogenetic Analysis of Feline Coronavirus Strains in an Epizootic Outbreak of Feline Infectious Peritonitis2013
Detection of Ascitic Feline Coronavirus RNA from Cats with Clinically Suspected Feline Infectious Peritonitis2013
Clinical and Molecular Relationships between COVID-19 and Feline Infectious Peritonitis (FIP)2022